The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia - Wikidata - awgldk - TriplyDB

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q28271441

about

Cardioprotective interventions for cancer patients receiving anthracyclines Cardioprotective interventions for cancer patients receiving anthracyclines Doxorubicin cardiomyopathy Cardiotoxicity in childhood cancer survivors: strategies for prevention and management Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure Cardiac toxicity in cancer survivors NADPH oxidases in heart failure: poachers or gamekeepers?Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs Treatment, behavioral, and psychosocial components of cardiovascular disease risk among survivors of childhood and young adult cancer Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity Prediction of cancer drugs by chemical-chemical interactions Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Frequency of elevations in markers of cardiomyocyte damage in otherwise healthy newborns.Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications.Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study.The minipig as a new model for the evaluation of doxorubicin-induced chronic toxicity.Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis.Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients Clinical research directions in pediatric cardiology.Cardiovascular disease in adult survivors of childhood cancer.Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.Cardiac biomarkers in HIV-exposed uninfected children.Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?Dexrazoxane for the treatment of chemotherapy-related side effects.Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure.Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy.Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants?Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Anthracycline-associated cardiotoxicity in survivors of childhood cancer.Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury A Novel Angiotensin Type I Receptor Antagonist, Fimasartan, Prevents Doxorubicin-induced Cardiotoxicity in Rats.

P2860

Q24236338-4670B7F9-D895-4917-9366-E4FBFF82DBCA Q24243021-A561B2F0-CC5C-466B-89E0-349890CFBA81 Q24606920-20DD6C9A-04E3-40BB-A8FE-77BC0D784365 Q24628695-655490EC-7100-4A3D-8C65-D20656EEA383 Q26742059-CB8ECEA4-4FF8-46DC-9F0E-2B0F2BCC78B0 Q26823592-8BFFB92B-B0C1-443D-9210-D809B702CC43 Q26851957-F95B14A8-B6E7-4CF2-9F51-2427FA15A9AB Q27001094-AC7334DB-7D2F-45FA-8B9F-2C82DC8FB74F Q27007849-947794D5-B6A9-4845-BA06-87B5D10BB393 Q27027354-8505A9BE-CF0A-4622-95EA-D0502130D4A3 Q28070311-F2B0D58E-4FDE-4273-B84E-C9DD051AEAE3 Q28088408-18160FD1-8200-45EE-8683-47A7EE581B2C Q28301317-DDE58779-3C22-4D9A-B332-5C67C0CEEC86 Q28539449-1C4DED05-110A-45B9-BC93-BAF9A0F32164 Q28554422-FCEB5B82-AFA1-4C95-9DEE-A2744D94FDE1 Q30401812-BFDF5DBC-888C-4648-8B41-EF0CC21EAE03 Q30438569-B2205426-93AA-420B-BDA4-A4C44890D664 Q30487342-3F0FDF30-8E3A-4C42-BE15-4FEF0ED4BCE2 Q33270016-09E24BBA-F0E5-466E-A3C9-6F0B08438BF0 Q33400806-C96D0F3A-F8BB-4323-B308-7D1757768206 Q33427938-9B53A486-4F2F-4CA3-BA71-C2BFC00B5CF8 Q33615969-5DE662CC-549E-4844-A215-61070EFB181E Q33645760-20A87A90-F147-460D-89A9-572A45EF3937 Q33816471-76FDEBA6-5CCF-4335-9D72-98CFAC021D06 Q33944043-EA59ACCB-51EE-40FF-9449-827467C3C318 Q34042984-B97FC156-9FC0-4193-AD95-EFCCF78C97A4 Q34073681-AB7FF92A-6DD4-4B75-96B5-178115F7916B Q34081675-53588682-E4BD-4D34-B5F8-E5691BCA80F1 Q34102834-406EDCF4-E9C6-4444-A118-469558D6906E Q34211957-54950920-9DA4-49C5-8EAC-D4E5FC48F728 Q34241724-018DDC21-D975-4E16-AAAE-80F25E1ABAFA Q34253158-441F9AF3-75F0-45A9-950B-42968345D9DB Q34322162-814FE3BE-9B5B-406E-8F1E-A7030133389C Q34466688-BE1C96D5-2BD3-4078-91BF-A01A27392991 Q34563378-48A7AD43-9FD4-4D14-9822-E37D590F3565 Q34564943-1003C7E7-C205-484F-817E-A6DEF8AA0556 Q34572109-91F87793-EBF3-4F08-8181-41127E548B58 Q34626238-65F102A3-BE37-41E2-A160-8B600B28D473 Q35039202-FD8FEF58-D31F-4EDF-834F-B9767B7EDC11 Q35553674-A79BED7E-327E-4E4E-939D-FE33A3884DEF

P2860

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

http://www.wikidata.org/entity/Q28271441

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@ast

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@en

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@nl

type

label

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@ast

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@en

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@nl

prefLabel

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@ast

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@en

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@nl

P1433

Q28271441-EDAEFE3C-94A3-4D14-9699-37499731EDD5

P1476

Q28271441-2B7CEBAF-306C-4CC8-A6CB-30DF7712F4E1

P2093

Q28271441-11CB5250-7FA6-4A4D-9477-65F2F11AECAF

Q28271441-17A940DD-853F-4FC4-A56E-ADB211A32C7F

Q28271441-4953D8FC-2526-410C-AC90-DB8473D2A9C9

Q28271441-5391A527-CDDF-4169-B278-E5E11EF494C9

Q28271441-63D2937F-7357-4814-86CB-A1BF77138B72

Q28271441-8483FEBC-53AE-4E6C-AEDF-A0213E2AFA39

Q28271441-9233CBAE-E41C-475D-8A01-0EBFA9CFA553

Q28271441-923579CB-2A62-4FDB-947B-1279EF04E935

Q28271441-9E2E07C6-ABCC-4E2B-8057-9BC618F12775

Q28271441-ABCDB1C0-5872-488D-81EB-6ED20802D52A

P304

Q28271441-DFE86988-A1A3-4376-9D9B-2F9003383FC4

P31

Q28271441-1A660946-4111-48BA-82BD-90DDB3BFC778

P3181

Q28271441-5BB18A11-340D-495E-9124-55852CEB0875

P356

Q28271441-7CE9AA37-06B8-4B13-AF22-A7EB5BD87C3D

P407

Q28271441-933A6779-4F88-47D8-AA48-8C025587E6F6

P433

Q28271441-EFA571E6-46D0-4555-A483-5DD763B2BF86

P478

Q28271441-B25DA61B-2C5B-4600-A824-9F8F495EB3AA

P577

Q28271441-3CD49D59-657F-4F27-A25F-26240BDFC5BF

P698

Q28271441-A71AE184-D6E0-40DB-82B2-DAB272FC7A3F

P921

Q28271441-BA9062D3-1446-4DAA-843A-0468311899BC

P3181

P356

P1433

The New England Journal of Medicine

P1476

The effect of dexrazoxane on m ...... h acute lymphoblastic leukemia

@en

P2093

Albert Moghrabi

http://www.w3.org/2001/XMLSchema#string

Barbara L Asselin

http://www.w3.org/2001/XMLSchema#string

Craig A Hurwitz

http://www.w3.org/2001/XMLSchema#string

Donna E Levy

http://www.w3.org/2001/XMLSchema#string

Lewis B Silverman

http://www.w3.org/2001/XMLSchema#string

Luis A Clavell

http://www.w3.org/2001/XMLSchema#string

Marshall A Schorin

http://www.w3.org/2001/XMLSchema#string

Nader Rifai

http://www.w3.org/2001/XMLSchema#string

Richard D Gelber

http://www.w3.org/2001/XMLSchema#string

Ronald D Barr

http://www.w3.org/2001/XMLSchema#string

P304

145-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1946315

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA035153

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

351

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15247354

http://www.w3.org/2001/XMLSchema#string

P921